Large-scale multimodal data has become a driving force in life sciences research, and your organization can’t afford to miss this opportunity. How is large-scale multimodal data fitting into your plan and budget for 2025? Do you have the right technology to advance this work effectively and efficiently across researchers, informatics and ML teams? How will you prioritize a FAIR multi-omics platform to best leverage AI and machine learning? If you’re looking for answers to these questions, you’re not alone. In this webinar, we will explore the complex infrastructure map for -omics data and learn key evaluation criteria to inform durable decisions for your data platform that will drive drug discovery and development.
Chief Technology Officer, TileDB
TileDB is foundational software designed by scientists for scientific discovery. TileDB structures all data types, including data that does not fit into relational databases built for structured tabular data. Built on a powerful shape-shifting array database, TileDB handles the complexities of non-traditional “unstructured” multimodal data, such as genomic variants, bulk and single-cell transcriptomics, proteomics, biomedical imaging and the frontier data of the future.
Used by big pharma and biotechs to power their multi-omic FAIR data platforms, TileDB is the destination for scientific breakthroughs where frontier multimodal data is driving drug discovery.